Novan (NASDAQ:NOVN) posted its earnings results on Wednesday. The company reported ($0.17) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.22) by $0.05, Fidelity Earnings reports.
Shares of NASDAQ:NOVN opened at $0.40 on Friday. The company has a market cap of $19.45 million, a P/E ratio of -0.34 and a beta of -0.31. The stock’s 50-day moving average is $0.38 and its 200-day moving average is $1.06. Novan has a 52-week low of $0.22 and a 52-week high of $3.72.
Several equities analysts have commented on NOVN shares. Zacks Investment Research raised shares of Novan from a “hold” rating to a “buy” rating and set a $0.75 target price on the stock in a research report on Thursday, March 12th. ValuEngine raised Novan from a “hold” rating to a “buy” rating in a research report on Thursday, April 2nd.
Novan, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum.
Further Reading: What is the Book Value of a Share?
Receive News & Ratings for Novan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novan and related companies with MarketBeat.com's FREE daily email newsletter.